THE US Food and Drug
Administration has approved a new
formulation of Sanofi Aventis’
Taxotere (docetaxel) intravenous
chemotherapeutic agent.
Indicated for use in treating
patients at specific stages of 5
types of cancer: metastatic and
adjuvant breast cancer, metastatic
androgen independent prostate
cancer, advanced non-small cell
lung cancer, advanced gastric
adenocarcinoma and locally
advanced squamous cell
carcinoma of the head and neck,
the new formula comes in a onevial
dose which eliminates the
need for initial dilution.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Aug 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.